ArticleAllergy, asthma & immunology research2025
Allergic-Specific Immunotherapy Using Injectable
Article in Allergy, asthma & immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates the allergic responses in a murine allergic rhinitis model.Human vaccines & immunotherapeutics · 2026Article
- Spinacetin, an Anti-Inflammatory Natural Compound with Multiple Pharmacological Properties.Current issues in molecular biology · 2026Review
- Single-cell transcriptome sequencing reveals immunological mechanisms by which recombinant Echinococcus granulosus P29 protein alleviates airway inflammation in mice with allergic asthma.Parasites & vectors · 2026Article
- Protective effects of sodium hyaluronate nasal spray on murine nasal mucosa via preservation of airway surface liquid and mucociliary clearance.Frontiers in allergy · 2026Article
- Serum metabolomic profiling identifies taurolithocholic acid as a predictor of HDM-SCIT response in allergic rhinitis: clinical discovery and experimental validation.Frontiers in immunology · 2026Article
- Hyaluronic Acid and Its Synthases-Current Knowledge.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeWe present a convenient and safe allergen-specific immunotherapy using injectable hyaluronic acid (HA) hydrogel containing house dust mite (HDM) crosslinked via visible-light-induced thiol-ene reaction.
methodsWe developed 2 types of HDM-containing HA hydrogels, namely thiolated HA (SH-HA) + methacrylated HA (MA-HA) (Gel-1) and 4-arm poly (ethylene glycol) (PEG)-SH + MA-HA (Gel-2). The immunotherapeutic effect of the hydrogels was tested using a murine model of allergic rhinitis. Sensitized mice received 3 subcutaneous injections of the HDM extract (subcutaneous immunotherapy [SCIT] group) or phosphate buffer saline (negative and positive control) at 2-day intervals. Mice in the HA hydrogel immunotherapy groups received one subcutaneous injection of each HA hydrogel precursor solution that formed hydrogel by transmitting blue light through the skin. All except the negative control received HDM extract intranasally for 5 days. Nasal symptoms, ear swelling, eosinophil count, antibody levels, and histopathology of the nasal mucosa were analyzed.
resultsAll HDM-containing immunotherapy groups exhibited reduced nasal symptoms, ear swelling, and eosinophil count in nasopharyngeal lavage compared to the positive control group. Eosinophils, mast cells, and goblet cells in the nasal mucosa decreased in all treatment groups compared to the positive control group. The serum levels of HDM-specific immunoglobulin G (IgG)1 increased in all treatment groups; however, IgG2a levels increased only in the SCIT and Gel-2 groups. Interleukin (IL)-4, 13, and 17 decreased in all treatment groups compared to those in the positive control group, whereas IL-10 level increased only in the SCIT and Gel-2 groups. SCIT and Gel-2 treatment showed similar capability to induce regulatory T cells.
conclusionsInjectable HA hydrogel containing HDM reduced allergic symptoms and induced tolerance in a murine model of allergic rhinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.